Sign In

17.5 : Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.

Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and the influx of calcium ions into neurons.

The inhibition of T-type calcium channels has a profound impact on neuronal excitability. When these channels are blocked, the rate of depolarization in neurons slows down. This slowing of depolarization has the therapeutic effect of diminishing seizure activity. Calcium channel blockers help stabilize neuronal function, making them an essential component of epilepsy management.

Several calcium channel blockers are commonly employed in the treatment of epilepsy, including:

1. Ethosuximide (Zarontin): Ethosuximide is a well-known antiepileptic medication primarily targeting T-type calcium channels. It is particularly effective in managing absence seizures.

2. Sodium valproate (Depakote):Although mentioned earlier as a GABA pathway potentiator, sodium valproate is a versatile drug and broad-spectrum anticonvulsant that has some calcium channel blocking properties. It helps reduce seizure activity by regulating calcium ion flow in neurons.

3.Zonisamide (Zonegran): Zonisamide is another calcium channel blocker used in epilepsy treatment. It plays a role in stabilizing neuronal excitability, thereby mitigating seizures.

When administered orally, calcium channel blockers are efficiently absorbed by the body. While generally well tolerated, some individuals may experience side effects. Common side effects include nausea, vomiting, and central nervous system effects like drowsiness, tremors, and dizziness. Rare side effects may include skin rash, weight loss, and cognitive difficulties.

From Chapter 17:

article

Now Playing

17.5 : Antiepileptic Drugs: Calcium Channel Blockers

Pharmacotherapy of the Epilepsies

26 Views

article

17.1 : Arteries of the Lower Limbs

Pharmacotherapy of the Epilepsies

20 Views

article

17.2 : Seizures: Classification

Pharmacotherapy of the Epilepsies

36 Views

article

17.3 : Antiepileptic Drugs: Sodium Channel Blockers

Pharmacotherapy of the Epilepsies

26 Views

article

17.4 : Antiepileptic Drugs: GABAergic Pathway Potentiators

Pharmacotherapy of the Epilepsies

63 Views

article

17.6 : Antiepileptic Drugs: Glutamate Antagonists

Pharmacotherapy of the Epilepsies

48 Views

article

17.7 : Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Pharmacotherapy of the Epilepsies

17 Views

article

17.8 : Antiepileptic Drugs: Potassium Channel Activators

Pharmacotherapy of the Epilepsies

17 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved